Advanced search
1 file | 1.37 MB Add to list

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

Author
Organization
Abstract
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.
Keywords
PLACEBO-CONTROLLED TRIAL, ACTIVE ANKYLOSING-SPONDYLITIS, DISEASE-ACTIVITY SCORE, RADIOGRAPHIC SACROILIITIS PROGRESSION, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, NECROSIS FACTOR AGENTS, DOUBLE-BLIND, CROHNS-DISEASE, CERTOLIZUMAB PEGOL, 1ST UPDATE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.37 MB

Citation

Please use this url to cite or link to this publication:

MLA
van der Heijde, Désirée et al. “2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis.” ANNALS OF THE RHEUMATIC DISEASES 76.6 (2017): 978–991. Print.
APA
van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., et al. (2017). 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. ANNALS OF THE RHEUMATIC DISEASES, 76(6), 978–991.
Chicago author-date
van der Heijde, Désirée, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, et al. 2017. “2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis.” Annals of the Rheumatic Diseases 76 (6): 978–991.
Chicago author-date (all authors)
van der Heijde, Désirée, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, and Jürgen Braun. 2017. “2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis.” Annals of the Rheumatic Diseases 76 (6): 978–991.
Vancouver
1.
van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):978–91.
IEEE
[1]
D. van der Heijde et al., “2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis,” ANNALS OF THE RHEUMATIC DISEASES, vol. 76, no. 6, pp. 978–991, 2017.
@article{8522004,
  abstract     = {To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.},
  author       = {van der Heijde, Désirée and Ramiro, Sofia and Landewé, Robert and Baraliakos, Xenofon and Van den Bosch, Filip and Sepriano, Alexandre and Regel, Andrea and Ciurea, Adrian and Dagfinrud, Hanne and Dougados, Maxime and van Gaalen, Floris and Géher, Pál and van der Horst-Bruinsma, Irene and Inman, Robert D and Jongkees, Merryn and Kiltz, Uta and Kvien, Tore K and Machado, Pedro M and Marzo-Ortega, Helena and Molto, Anna and Navarro-Compàn, Victoria and Ozgocmen, Salih and Pimentel-Santos, Fernando M and Reveille, John and Rudwaleit, Martin and Sieper, Jochen and Sampaio-Barros, Percival and Wiek, Dieter and Braun, Jürgen},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keywords     = {PLACEBO-CONTROLLED TRIAL,ACTIVE ANKYLOSING-SPONDYLITIS,DISEASE-ACTIVITY SCORE,RADIOGRAPHIC SACROILIITIS PROGRESSION,NONSTEROIDAL ANTIINFLAMMATORY DRUGS,NECROSIS FACTOR AGENTS,DOUBLE-BLIND,CROHNS-DISEASE,CERTOLIZUMAB PEGOL,1ST UPDATE},
  language     = {eng},
  number       = {6},
  pages        = {978--991},
  title        = {2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2016-210770},
  volume       = {76},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: